20 ans de Genopole : le biocluster veut participer à la constitution de filières pour l’innovation en santé et en environnement
Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases
Sofradir elected to Photonics21 Board of Stakeholders
Vygon Group acquires 20 per cent of Canadian OxyNov
Ypso-Facto invests an additional €1M in the development of software for the design and evaluation of chemical and biotechnological processes
Kyomed becomes KYomed INNOV
Sofradir and ULIS undergo structural reorganization to improve efficiency
Genopole a attiré plus de 100 chercheurs et chercheuses depuis 20 ans
